Stem definition | Drug id | CAS RN |
---|---|---|
mucolytics | 66 | 616-91-1 |
Dose | Unit | Route |
---|---|---|
1.60 | g | Inhal.solution |
0.50 | g | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 61.28 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 5 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.55 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.17 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 5.50 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 14, 1963 | FDA | APOTHECON |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Body tinea | 98.62 | 14.05 | 27 | 11537 | 1174 | 53336328 |
Infection susceptibility increased | 82.63 | 14.05 | 28 | 11536 | 2509 | 53334993 |
Inhibitory drug interaction | 77.45 | 14.05 | 26 | 11538 | 2264 | 53335238 |
Impaired quality of life | 68.17 | 14.05 | 29 | 11535 | 4842 | 53332660 |
Glucose tolerance impaired | 62.50 | 14.05 | 28 | 11536 | 5292 | 53332210 |
Chronic obstructive pulmonary disease | 53.39 | 14.05 | 66 | 11498 | 61007 | 53276495 |
Bone density decreased | 50.77 | 14.05 | 31 | 11533 | 11033 | 53326469 |
Stevens-Johnson syndrome | 48.05 | 14.05 | 41 | 11523 | 24541 | 53312961 |
Acute hepatic failure | 48.04 | 14.05 | 35 | 11529 | 16685 | 53320817 |
Rheumatoid arthritis | 45.41 | 14.05 | 7 | 11557 | 314524 | 53022978 |
Purpura | 43.73 | 14.05 | 28 | 11536 | 10825 | 53326677 |
Toxicity to various agents | 42.58 | 14.05 | 124 | 11440 | 219474 | 53118028 |
Poor quality sleep | 42.52 | 14.05 | 33 | 11531 | 17290 | 53320212 |
Toxic epidermal necrolysis | 41.44 | 14.05 | 37 | 11527 | 23513 | 53313989 |
Tongue oedema | 39.37 | 14.05 | 19 | 11545 | 4248 | 53333254 |
Metabolic acidosis | 39.10 | 14.05 | 47 | 11517 | 42195 | 53295307 |
Hepatic encephalopathy | 38.83 | 14.05 | 26 | 11538 | 10833 | 53326669 |
Overdose | 37.15 | 14.05 | 76 | 11488 | 107660 | 53229842 |
Hyperlipidaemia | 37.02 | 14.05 | 32 | 11532 | 19483 | 53318019 |
Oral herpes | 34.76 | 14.05 | 32 | 11532 | 21147 | 53316355 |
Impaired work ability | 32.76 | 14.05 | 26 | 11538 | 14064 | 53323438 |
Anaphylactoid reaction | 32.58 | 14.05 | 16 | 11548 | 3715 | 53333787 |
Hepatotoxicity | 32.55 | 14.05 | 35 | 11529 | 27845 | 53309657 |
Thrombocytopenia | 31.46 | 14.05 | 83 | 11481 | 138644 | 53198858 |
Drug-induced liver injury | 31.19 | 14.05 | 35 | 11529 | 29198 | 53308304 |
Hypercapnia | 30.81 | 14.05 | 17 | 11547 | 5010 | 53332492 |
Product dose omission issue | 30.72 | 14.05 | 3 | 11561 | 191617 | 53145885 |
Immune-mediated pancreatitis | 30.34 | 14.05 | 6 | 11558 | 59 | 53337443 |
Joint swelling | 30.06 | 14.05 | 7 | 11557 | 234631 | 53102871 |
Rash maculo-papular | 27.36 | 14.05 | 33 | 11531 | 29716 | 53307786 |
Congenital central hypoventilation syndrome | 27.32 | 14.05 | 5 | 11559 | 31 | 53337471 |
Pneumonia | 26.75 | 14.05 | 165 | 11399 | 407004 | 52930498 |
Drug interaction | 26.68 | 14.05 | 106 | 11458 | 219223 | 53118279 |
Brain oedema | 25.24 | 14.05 | 22 | 11542 | 13536 | 53323966 |
Erysipelas | 24.95 | 14.05 | 17 | 11547 | 7284 | 53330218 |
Herpes simplex hepatitis | 24.87 | 14.05 | 7 | 11557 | 337 | 53337165 |
Respiratory failure | 23.66 | 14.05 | 61 | 11503 | 100451 | 53237051 |
Skin disorder | 23.46 | 14.05 | 28 | 11536 | 24930 | 53312572 |
Coma | 22.98 | 14.05 | 45 | 11519 | 61738 | 53275764 |
Postresuscitation encephalopathy | 22.76 | 14.05 | 4 | 11560 | 19 | 53337483 |
Model for end stage liver disease score increased | 22.27 | 14.05 | 4 | 11560 | 22 | 53337480 |
Post procedural haematoma | 21.77 | 14.05 | 9 | 11555 | 1399 | 53336103 |
Coagulopathy | 21.72 | 14.05 | 24 | 11540 | 19674 | 53317828 |
Tongue exfoliation | 21.58 | 14.05 | 5 | 11559 | 109 | 53337393 |
Hepatic failure | 21.12 | 14.05 | 32 | 11532 | 35774 | 53301728 |
Sputum increased | 20.72 | 14.05 | 10 | 11554 | 2236 | 53335266 |
Brain herniation | 19.61 | 14.05 | 11 | 11553 | 3345 | 53334157 |
Pain | 19.59 | 14.05 | 64 | 11500 | 588334 | 52749168 |
Face oedema | 19.51 | 14.05 | 23 | 11541 | 20217 | 53317285 |
Oliguria | 19.26 | 14.05 | 16 | 11548 | 9222 | 53328280 |
Arthralgia | 19.03 | 14.05 | 42 | 11522 | 439741 | 52897761 |
Hepatitis fulminant | 18.84 | 14.05 | 11 | 11553 | 3608 | 53333894 |
Respiratory tract oedema | 18.61 | 14.05 | 6 | 11558 | 460 | 53337042 |
Arthropathy | 18.55 | 14.05 | 4 | 11560 | 141449 | 53196053 |
Chronic hepatitis C | 18.43 | 14.05 | 5 | 11559 | 210 | 53337292 |
Cataract | 18.27 | 14.05 | 36 | 11528 | 49584 | 53287918 |
Respiratory distress | 18.23 | 14.05 | 29 | 11535 | 33798 | 53303704 |
Brain death | 17.96 | 14.05 | 10 | 11554 | 2998 | 53334504 |
General physical health deterioration | 17.83 | 14.05 | 71 | 11493 | 146871 | 53190631 |
Jaundice | 17.75 | 14.05 | 27 | 11537 | 30286 | 53307216 |
Systemic lupus erythematosus | 17.60 | 14.05 | 3 | 11561 | 125411 | 53212091 |
Contraindicated product administered | 17.45 | 14.05 | 4 | 11560 | 135625 | 53201877 |
Urogenital haemorrhage | 17.35 | 14.05 | 5 | 11559 | 262 | 53337240 |
Adrenocorticotropic hormone deficiency | 17.23 | 14.05 | 5 | 11559 | 269 | 53337233 |
Autoimmune hepatitis | 16.50 | 14.05 | 14 | 11550 | 8304 | 53329198 |
Anaphylactic shock | 16.50 | 14.05 | 22 | 11542 | 21871 | 53315631 |
Lip pain | 16.46 | 14.05 | 8 | 11556 | 1816 | 53335686 |
Delirium | 16.41 | 14.05 | 31 | 11533 | 41398 | 53296104 |
Activated partial thromboplastin time prolonged | 16.35 | 14.05 | 13 | 11551 | 7046 | 53330456 |
Macroangiopathy | 16.17 | 14.05 | 4 | 11560 | 116 | 53337386 |
Decerebrate posture | 16.14 | 14.05 | 4 | 11560 | 117 | 53337385 |
Treatment failure | 16.10 | 14.05 | 4 | 11560 | 128399 | 53209103 |
Dose calculation error | 16.01 | 14.05 | 4 | 11560 | 121 | 53337381 |
Junctional ectopic tachycardia | 15.76 | 14.05 | 4 | 11560 | 129 | 53337373 |
Acute respiratory distress syndrome | 15.41 | 14.05 | 22 | 11542 | 23310 | 53314192 |
Medication error | 15.39 | 14.05 | 28 | 11536 | 36337 | 53301165 |
Flank pain | 15.34 | 14.05 | 17 | 11547 | 13979 | 53323523 |
Injection site pain | 15.29 | 14.05 | 3 | 11561 | 113388 | 53224114 |
Musculoskeletal stiffness | 15.16 | 14.05 | 4 | 11560 | 123364 | 53214138 |
Intentional overdose | 15.00 | 14.05 | 40 | 11524 | 67165 | 53270337 |
Acute kidney injury | 14.85 | 14.05 | 100 | 11464 | 253768 | 53083734 |
Swelling | 14.59 | 14.05 | 12 | 11552 | 191093 | 53146409 |
Pyrexia | 14.45 | 14.05 | 142 | 11422 | 403051 | 52934451 |
Soft tissue swelling | 14.39 | 14.05 | 6 | 11558 | 953 | 53336549 |
Multiple organ dysfunction syndrome | 14.36 | 14.05 | 35 | 11529 | 55642 | 53281860 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxic epidermal necrolysis | 72.69 | 12.91 | 60 | 11713 | 20533 | 32481220 |
Dyspnoea | 57.74 | 12.91 | 271 | 11502 | 361774 | 32139979 |
Pneumonia | 57.44 | 12.91 | 267 | 11506 | 354985 | 32146768 |
Congenital hiatus hernia | 50.02 | 12.91 | 13 | 11760 | 271 | 32501482 |
General physical health deterioration | 45.59 | 12.91 | 117 | 11656 | 115142 | 32386611 |
Stevens-Johnson syndrome | 45.16 | 12.91 | 44 | 11729 | 18665 | 32483088 |
Chronic obstructive pulmonary disease | 38.79 | 12.91 | 66 | 11707 | 48687 | 32453066 |
Breath sounds abnormal | 33.31 | 12.91 | 23 | 11750 | 6022 | 32495731 |
Respiratory failure | 28.09 | 12.91 | 94 | 11679 | 107088 | 32394665 |
Productive cough | 25.57 | 12.91 | 45 | 11728 | 34071 | 32467682 |
Cell death | 25.33 | 12.91 | 14 | 11759 | 2472 | 32499281 |
Product dose omission issue | 24.28 | 12.91 | 4 | 11769 | 102571 | 32399182 |
Systemic infection | 24.20 | 12.91 | 13 | 11760 | 2170 | 32499583 |
Cyanosis | 23.91 | 12.91 | 26 | 11747 | 12527 | 32489226 |
Klebsiella infection | 23.48 | 12.91 | 21 | 11752 | 7991 | 32493762 |
Bilirubin conjugated abnormal | 23.09 | 12.91 | 6 | 11767 | 125 | 32501628 |
Completed suicide | 21.04 | 12.91 | 4 | 11769 | 92513 | 32409240 |
Middle ear inflammation | 20.77 | 12.91 | 3 | 11770 | 0 | 32501753 |
Bronchiectasis | 19.85 | 12.91 | 18 | 11755 | 6974 | 32494779 |
Wrong dose | 19.28 | 12.91 | 7 | 11766 | 457 | 32501296 |
Cough | 19.16 | 12.91 | 100 | 11673 | 138717 | 32363036 |
Malignant melanoma in situ | 18.69 | 12.91 | 9 | 11764 | 1194 | 32500559 |
Oral herpes | 18.54 | 12.91 | 15 | 11758 | 4982 | 32496771 |
Medication error | 17.24 | 12.91 | 30 | 11743 | 22505 | 32479248 |
Death | 17.06 | 12.91 | 76 | 11697 | 382441 | 32119312 |
Acute respiratory failure | 16.69 | 12.91 | 34 | 11739 | 28694 | 32473059 |
Deafness bilateral | 16.39 | 12.91 | 8 | 11765 | 1094 | 32500659 |
Bronchospasm | 16.33 | 12.91 | 20 | 11753 | 10935 | 32490818 |
Product prescribing error | 16.07 | 12.91 | 27 | 11746 | 19690 | 32482063 |
Nikolsky's sign | 15.50 | 12.91 | 5 | 11768 | 228 | 32501525 |
Multiple organ dysfunction syndrome | 15.47 | 12.91 | 58 | 11715 | 69796 | 32431957 |
Drug abuse | 15.28 | 12.91 | 5 | 11768 | 80238 | 32421515 |
Kidney rupture | 15.09 | 12.91 | 5 | 11768 | 248 | 32501505 |
Acidosis | 14.89 | 12.91 | 19 | 11754 | 10827 | 32490926 |
Graft loss | 14.74 | 12.91 | 7 | 11766 | 901 | 32500852 |
Pyrexia | 14.46 | 12.91 | 178 | 11595 | 319790 | 32181963 |
Skin odour abnormal | 14.31 | 12.91 | 7 | 11766 | 961 | 32500792 |
Acute hepatic failure | 13.69 | 12.91 | 20 | 11753 | 12949 | 32488804 |
Septic shock | 13.43 | 12.91 | 55 | 11718 | 68934 | 32432819 |
Full blood count abnormal | 13.37 | 12.91 | 10 | 11763 | 2963 | 32498790 |
Intestinal prolapse | 13.36 | 12.91 | 4 | 11769 | 142 | 32501611 |
Skin haemorrhage | 13.35 | 12.91 | 11 | 11762 | 3748 | 32498005 |
Anaphylactoid reaction | 13.23 | 12.91 | 9 | 11764 | 2299 | 32499454 |
Empyema | 13.20 | 12.91 | 10 | 11763 | 3021 | 32498732 |
Source | Code | Description |
---|---|---|
ATC | R05CB01 | RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS Mucolytics |
ATC | S01XA08 | SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals |
ATC | V03AB23 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
FDA PE | N0000008867 | Decreased Respiratory Secretion Viscosity |
FDA EPC | N0000175429 | Antidote |
FDA MoA | N0000175547 | Reduction Activity |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000975 | Antioxidants |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D005100 | Expectorants |
MeSH PA | D016166 | Free Radical Scavengers |
MeSH PA | D019141 | Respiratory System Agents |
FDA EPC | N0000175776 | Mucolytic |
FDA PE | N0000175960 | Increased Glutathione Concentration |
FDA EPC | N0000175961 | Antidote for Acetaminophen Overdose |
CHEBI has role | CHEBI:22586 | antioxidants |
CHEBI has role | CHEBI:35441 | anti-infective drugs |
CHEBI has role | CHEBI:36044 | anti-virus drug |
CHEBI has role | CHEBI:48578 | free-radical scavenger |
CHEBI has role | CHEBI:73336 | vulneraries |
CHEBI has role | CHEBI:74529 | Tylenol poisoning antidotes |
CHEBI has role | CHEBI:77034 | mucolytics |
CHEBI has role | CHEBI:77746 | H. sapiens metabolites |
CHEBI has role | CHEBI:173084 | ferroptosis inhibitors |
CHEBI has role | CHEBI:176497 | anti-aging drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Bronchiectasis | indication | 12295008 | DOID:9563 |
Amyloidosis | indication | 17602002 | DOID:9120 |
Bronchitis | indication | 32398004 | DOID:6132 |
General anesthesia | indication | 50697003 | |
Poisoning by acetaminophen | indication | 70273001 | |
Cystic fibrosis of the lung | indication | 86555001 | |
Atelectasis due to Mucous Obstruction | indication | ||
Thick Bronchial Secretions | indication | ||
Contrast Media-Induced Nephrotoxicity Prevention | indication | ||
Meconium ileus | off-label use | 206523001 | |
Bronchial Studies | off-label use | ||
Bronchospasm | contraindication | 4386001 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Esophageal varices | contraindication | 28670008 | |
Low blood pressure | contraindication | 45007003 | |
Decreased respiratory function | contraindication | 80954004 | |
Acute exacerbation of asthma | contraindication | 708038006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.22 | acidic |
pKa2 | 9.96 | acidic |
pKa3 | 12.92 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
6GM/30ML (200MG/ML) | ACETADOTE | CUMBERLAND PHARMS | N021539 | Jan. 23, 2004 | RX | INJECTABLE | INTRAVENOUS | 8399445 | Aug. 24, 2025 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
6GM/30ML (200MG/ML) | ACETADOTE | CUMBERLAND PHARMS | N021539 | Jan. 23, 2004 | RX | INJECTABLE | INTRAVENOUS | 8653061 | Aug. 24, 2025 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
6GM/30ML (200MG/ML) | ACETADOTE | CUMBERLAND PHARMS | N021539 | Jan. 23, 2004 | RX | INJECTABLE | INTRAVENOUS | 9327028 | July 21, 2031 | COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY |
6GM/30ML (200MG/ML) | ACETADOTE | CUMBERLAND PHARMS | N021539 | Jan. 23, 2004 | RX | INJECTABLE | INTRAVENOUS | 8722738 | April 6, 2032 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
2.5GM | CETYLEV | ARBOR PHARMS LLC | N207916 | Jan. 29, 2016 | DISCN | TABLET, EFFERVESCENT | ORAL | 8747894 | May 8, 2032 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
2.5GM | CETYLEV | ARBOR PHARMS LLC | N207916 | Jan. 29, 2016 | DISCN | TABLET, EFFERVESCENT | ORAL | 9561204 | May 8, 2032 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
500MG | CETYLEV | ARBOR PHARMS LLC | N207916 | Jan. 29, 2016 | DISCN | TABLET, EFFERVESCENT | ORAL | 8747894 | May 8, 2032 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
500MG | CETYLEV | ARBOR PHARMS LLC | N207916 | Jan. 29, 2016 | DISCN | TABLET, EFFERVESCENT | ORAL | 9561204 | May 8, 2032 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Cytochrome c | Enzyme | WOMBAT-PK | |||||||
Vascular endothelial growth factor A | Secreted | WOMBAT-PK | |||||||
Superoxide dismutase [Mn], mitochondrial | Enzyme | WOMBAT-PK | |||||||
Glutathione synthetase | Enzyme | MODULATOR | DRUGBANK | ||||||
Cystine/glutamate transporter | Transporter | MODULATOR | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
4018810 | VUID |
N0000147113 | NUI |
D00221 | KEGG_DRUG |
197 | RXNORM |
C0001047 | UMLSCUI |
CHEBI:28939 | CHEBI |
1ZT | PDB_CHEM_ID |
SC2 | PDB_CHEM_ID |
CHEMBL600 | ChEMBL_ID |
DB06151 | DRUGBANK_ID |
D000111 | MESH_DESCRIPTOR_UI |
12035 | PUBCHEM_CID |
1535 | INN_ID |
10945 | IUPHAR_LIGAND_ID |
WYQ7N0BPYC | UNII |
4127 | MMSL |
48605 | MMSL |
893 | MMSL |
d00762 | MMSL |
000720 | NDDF |
003524 | NDDF |
387440002 | SNOMEDCT_US |
77731008 | SNOMEDCT_US |
4018810 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3307 | SOLUTION | 100 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-3308 | SOLUTION | 200 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-7504 | INHALANT | 100 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-7510 | INHALANT | 100 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-7604 | INHALANT | 200 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-7610 | INHALANT | 200 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-7630 | INHALANT | 200 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0805 | INJECTION | 200 mg | INTRAVENOUS | NDA | 22 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-660 | INJECTION | 200 mg | INTRAVENOUS | ANDA | 22 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-812 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | ANDA | 22 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-812 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | ANDA | 22 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-0104 | INJECTION | 200 mg | INTRAVENOUS | ANDA | 22 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5670 | SOLUTION | 200 mg | ORAL | ANDA | 18 sections |
Acetylcysteine | Human Prescription Drug Label | 1 | 55150-259 | INJECTION, SOLUTION | 6 g | INTRAVENOUS | ANDA | 22 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-5730 | INHALANT | 100 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-5731 | INHALANT | 200 mg | RESPIRATORY (INHALATION) | ANDA | 18 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-690 | SOLUTION | 200 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-690 | SOLUTION | 200 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-691 | SOLUTION | 100 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-692 | SOLUTION | 200 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-693 | SOLUTION | 100 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-694 | SOLUTION | 200 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-694 | SOLUTION | 200 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-695 | SOLUTION | 100 mg | ORAL | ANDA | 17 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-963 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | ANDA | 24 sections |
Acetylcysteine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-963 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | ANDA | 24 sections |
ACETADOTE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66220-207 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | NDA | 22 sections |
ACETYLCYSTEINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70710-1015 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | ANDA | 20 sections |
ACETYLCYSTEINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1412 | INJECTION, SOLUTION | 200 mg | INTRAVENOUS | ANDA | 1 sections |